dc.contributor.author |
Yakymenko, O. O. |
en |
dc.contributor.author |
Savytskyi, V. I. |
en |
dc.contributor.author |
Klochko, V. V. |
en |
dc.contributor.author |
Savytskyi, I. V. |
en |
dc.contributor.author |
Badiuk, N. S. |
en |
dc.date.accessioned |
2022-02-18T13:21:31Z |
|
dc.date.available |
2022-02-18T13:21:31Z |
|
dc.date.issued |
2021 |
|
dc.identifier.citation |
Changes in vasoconstructor-vasodilation potential of vessels in experimental antiphospholipid syndrome / O. O. Yakymenko, V. I. Savytskyi, V. V. Klochko et al // Pharmacology Online. 2021. Vol. 2. P. 819–826. |
en |
dc.identifier.uri |
https://repo.odmu.edu.ua:443/xmlui/handle/123456789/11237 |
|
dc.description.abstract |
As a result of our study, the development of endothelial dysfunction in experimental antiphospholipid syndrome is confirmed: an increase in the marker of ED (endothelin-1) and a pathological increase in vasoconstrictor potential on the background of weakening of vasodilatation. There was a pathological increase in the vasoconstrictor potential of blood vessels in animals simulated
antiphospholipid syndrome, as evidenced by an increase in endothelin-1 levels in the blood of rats (p <0,001). Violation of nitric oxide synthesis was detected against the background of the development of experimental antiphospholipid syndrome, which is confirmed by a marked decrease in the level of Snitrosothiols. The most pronounced normalization of vasoconstrictor-vasodilatory potential of vessels was found in rats, whose simulated antiphospholipid syndrome was corrected with warfarin, immunoglobulin and L-arginine solution. |
en |
dc.language.iso |
en |
en |
dc.subject |
antiphospholipid syndrome |
en |
dc.subject |
L-arginine |
en |
dc.subject |
endothelin-1 |
en |
dc.subject |
S-nitrosothiols |
en |
dc.subject |
immunoglobulin |
en |
dc.subject |
warfarin |
en |
dc.title |
Changes in vasoconstructor-vasodilation potential of vessels in experimental antiphospholipid syndrome |
en |
dc.type |
Article |
en |